I have some ideas. Yesterday's news was surprising only in the fact they completely stopped the trials for Oxycyte. The July conference call pretty much telegraphed that Oxycyte was no longer a priority. (Company Name change etc.) once yesterday's shareholder meeting was completed and all officers re-newed, they announced the end of Oxycyte trials, temp or permanent who knows. This company is now 100 % Levo driven. No resources will be expended on Oxycyte so funds will last longer until Levo is approved. Anyone who sold today panicked or was a holder for Oxycyte and decided to give up. People interested in Levo scooped up the cheap shares and the price rebounded quickly. Anyone that has bought in the past 12 months has done so primarily for Levo, especially the institutions. They are holding for phase III results. The other exciting development that happened today was an update on the oxybiomed website. It now says actively recruiting patients and the number of hospitals has increased to 5. Keep holding.
News 
Market Data 
Discover 
